An Open Label, Registry Study of the Safety of Iluvien 190 Micrograms Intravitreal Implant in Applicator
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Acronyms IRISS
- Sponsors Alimera Sciences
- 23 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Jan 2020.
- 23 Oct 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2020.
- 23 Oct 2017 Status changed from recruiting to active, no longer recruiting.